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Abstrak
Latar belakang: Lepra masih menjadi masalah kesehatan di Papua terutama di Kota Jayapura. 
Banyaknya kasus relaps dan default juga menjadi tantangan dalam eliminasi lepra di Jayapura. Kasus 
relaps dan riwayat default pada beberapa penelitian berkaitan dengan resistensi terhadap multi drug 
treatment (MDT). Tujuan penelitian ini adalah mendeteksi keberadaan mutasi gen rpoB M. leprae pada 
pasien relaps, default dan pasein yang kurang peka terhadap terapi MDT di Kota Jayapura.
Metode: Sampel diperoleh dari pasien yang terdiagnosis lepra dengan kriteria pasien relaps, default dan 
pasien yang terus bergejala setelah terapi MDT sebanyak 34 sampel. Sampel diambil dalam bentuk insisi 
kulit (skin silt) daun telinga. DNA diekstraksi dengan menggunakan kit Qiagen. Gen rpoB diamplifikasi 
melalui teknik PCR dan analisis nukleotida dilakukan melalui sekuensing. Analisis mutasi dilakukan 
melalui BLAST dengan basis data GenBank.  
Hasil: Sebanyak 34 sampel yang diperiksa, 9 diantaranya positif BTA sedangkan 25 yang lainnya negatif 
BTA. Pada hasil PCR, sampel yang berhasil teramplifikasi sebanyak 31 sampel, dan 3 sampel tidak 
teramplifikasi. Hasil BLAST menunjukkan bahwa tidak ditemukan adanya mutasi pada gen rpoB yang 
dapat menyebabkan resistensi terhadap rifampisin.
Kesimpulan: Kesimpulan dari penelitian ini adalah gen rpoB Mycobacterium leprae asal Jayapura 
tidak mengandung mutasi yang dapat menyebabkan terjadinya resistensi terhadap rifampisin. Dengan 
demikian rifampisin masih sensitif untuk pengobatan lepra di Kota Jayapura. (Health Science Journal of 
Indonesia 2018;9(1):31-6)
Kata kunci: Lepra, gen rpoB, rifampisin, Mycobacterium leprae.
Abstract
Background: Leprosy remains a prominent health problem in Papua especially in Jayapura City. Numerous 
cases of relapse and default are also challenges in leprosy elimination in Jayapura. Studies in Relapse 
cases and history of defaults revealed some resistance related to multi-drug treatment (MDT). The purpose 
of this study was to detect the presence of mutation in rpoB M. leprae gene in patient relapse, default and 
patients who are less sensitive to MDT therapy in Jayapura City.
Method: Samples were obtained from patients diagnosed with leprosy with criteria of relapse, default 
and symptomatic patients after receiving MDT therapy. A total of 34 samples were taken in the form of 
skin incision (skin silt) of the earlobe. DNA was extracted using Qiagen kit. rpoB gene from extracted 
DNA was amplified through PCR method followed by nucleotide sequences. Analysis of mutation was 
elaborated using BLAST according to GenBank database.
Result: 34 samples were examined, and 9 were positive for Ziehl-Neelsen (ZN)staining, while the 25 were negative. 
In the PCR results, the samples that successfully amplified were 31 samples, and 3 samples were not amplified. The 
results of BLAST indicated that no mutations in the rpoB gene found in which able to initiate resistance to rifampicin.
Conclusion: The conclusion of this study is the rpoB Mycobacterium leprae gene from Jayapura did not 
contain any mutations that could trigger resistance to rifampicin. Thus rifampicin is still sensitive for 
leprosy treatment in Jayapura City. (Health Science Journal of Indonesia 2018;9(1):31-6)
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Mycobacterium leprae is a bacterium that causes 
Hansen disease (leprosy). Leprosy is a skin infection 
disease, mucous membranes, and peripheral nerves.1 
This disease is slowly changing skin lesions into 
lesions that damage the face causing social stigma 
and isolation for leprosy patients.2 The prevalence of 
this disease has declined dramatically after the use 
MDT, but new incidental cases continue to occur.3 
The World Health Organization (WHO) decreed year 
2000 as a milestone in achieving leprosy elimination 
as an effort to control leprosy in the world. Indonesia 
achieved this target in the same year, but the 
development of the last 10 years has shown a static 
trend in the discovery of new cases. In the last 12 
years (2000-2011), the situation of leprosy disease in 
Indonesia has not changed and the disease remains a 
serious health problem.4   
Leprosy is one of the dominant diseases in Jayapura 
City, Papua. Papua is still a province with high 
burden.5 Based on the number of second-level defects 
and these are the provinces with the highest level of 
disability per 1 million people in Indonesia in 2013 
were Papua (26.88), Aceh (18.62), and West Papua 
(17.72). According to data from the Directorate 
General of Disease Control and Environmental 
Health, MoH RI 2014, the number of new cases of 
leprosy and case detection rate (CDR) for Papua 
Province by sex was 35.64 case detection rate (CDR) 
per 100,000 population for 2013,6 while for the year 
2014 experienced a slight decrease of 30,43 case 
detection rate (CDR) per 100,000 population.7
Rifampicin is a major component in chemotherapy 
used to treat leprosy and tuberculosis.8 On the 
recommendation of WHO, one type of treatment in 
a multi-drug therapy (MDT) program is rifampicin, 
although some leprosy patients are less susceptible 
to rifampicin and suspected of resistant M. leprae 
strains.9 Research conducted by Grosset et al reported 
that of 39 strains of M. leprae isolated from relapse 
patients, there were 22 strains that were resistant to 
rifampicin.10 Drug resistance characterized by initial 
treatment did not show progress or worsened, new 
lesions appeared and patient condition decreased.11 
Based on reports of cases of Jayapura City Health 
Office 2016, there were 34 patients with a history 
of relapse, defaults and some of which showed no 
significant improvement after taking MDT.12
Common identification methods for M. leprae are 
using microscopic observation and Ziehl-Nielsen 
Staining. These methods are generally used for the 
early screening of M. leprae although this method 
is less sensitive compared to PCR.13,14 The most 
important problem in drug-resistant detection of 
leprosy is M. leprae remains unable to be cultured 
by conventional method.15,16 The availability of 
genomic sequences from M. leprae and increased 
understanding of the genetic basis of drug resistance 
in mycobacteria led to the development of molecular 
methods for the detection of mutations associated 
with dapsone, rifampicin, and fluoroquinolone. In 
2008 the WHO recommended guidelines for a global 
disease survey on drug resistance by M. leprae 
using PCR sequencing. The guidelines contain 
DNA isolation from skin biopsies of multi-bacillary 
relapse patients (MB), PCR amplification of targeted 
DNA fragments containing drug resistance determining 
regions (DRDRs) from M. leprae using specific primers, 
sequencing, and alignment with sequence reference of 
DRDR M. leprae strain TN (NC_002677.1 GenBank) 
to determine the presence of drug resistance mutations.16  
The DRDR area for rifampicin is at about 1225 bp to 
1503 bp in the rpoB gene.16
Rapid information about susceptibility to a drug is 
crucial treatment effort for an individual especially 
the diseases caused by Mycobacterium by using 
rifampicin. Thus, it is necessary to do research to 
see the mutation in rpoB M. leprae gene. Research 
is expected to be used as information by the program 
that will be able to accelerate the decrease of 
incidence rate and cure of leprosy patient especially 
in Jayapura City.
METHODS 
This study was a cross section. This research has 
received approval from the Ethics Committee of 
National Institute of Health Research and Develop-
ment number LB.02.01/5.2/KE.048/2017. The study 
sample was ear incision taken from patients; relapsed, 
defaults, and patients who were less sensitive to 
treatment. The ear incisions that have been taken are then 
examined microscopically and molecularly. Microscopic 
examination was done by Ziehl-Neelsen (ZN) staining 
method. Assessment of microscopic examination results 
to determine the bacterial index performed according 
to the logarithm of Ridley.4 Molecular examination 
begins with DNA extraction process using Qiagen Kit, 
followed by Polymerase Chain Reaction (PCR) process. 
The PCR reagent mix  composition  consisted of  Go Taq 
Green Master Mix 2X, set primers (forward and reverse) 
10 pmol, DNA template 0,5 µg and nuclease free water. 
The primers used to amplify the rpoB gene in this study 
were WHOR1 5’-CAGACGCTGATCAATATCCGT-
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3’s as a forward primer and WHOR2 5’-CA-
GCGGTCAAGTATTCGATC-3’s as reverse pri-
mers. The first PCR results were followed by 
a second PCR using rpoB forward primers in 
CAATATCCGTCCGGTGGTC and reverse rpoB 
sequences in GTATTCGATCTCGTCGCTGA sequ­
ence. PCR was adjusted with pre-denaturation 
temperature at 95 oC for 5 minutes, denaturation at 94 
oC for 1 minute, annealing at 60 oC for 30 seconds, 
extension at 72 oC for 1 minute and final extension at 
72 oC for 10 minutes. The sequencing process uses 
ACGCTGATCAATATCCGTCC forward sequencing 
primers and CGACAATGAACCGATCAGAC 
reverse sequencing primer.17 The PCR conditions 
were arranged in sequence, pre­denaturation at 94°C 
for 5 minutes, denaturation at 95°C for 1 minute, 
Annealing at 60°C for 30 seconds, Extension at 72°C 
for 1 minute, and final extension at 74°C during 10 
minutes. The cycle was repeated for 40 cycles. The 
PCR result was purified by ExoSap IT with a ratio 
of 1:5. The purified PCR product was followed by 
a sequencing process. The sequencing cycle uses 
BigDye Terminator v3.1 5X, BigDye Terminator 
buffer 5X,  100 ng molded DNA, and primer 0,8 
pmol. DNA pGEM -3Zf was used as a positive 
control and Primary control -21 M13 as a positive 
control primer. The reaction of the sequencing cycle 
was carried out under conditions: 96oC 1 min, 96oC 
10 sec, 50oC 5 sec, 60 oC 4 min. The cycle was 
repeated 25 times later the result of the sequencing 
cycle is purified by XTerminator Solution and SAM 
solution 5:22,5. The sample volume used is 5 μL. 
The tube contained of premix got homogenised with 
samples by using vortex, for 30 minutes then in the 
centrifuge for 1 minute. The supernatant was inserted 
into a 20 μl wellbore slab and read by using 3500 
Genetic Analyser. The sequencing results were then 
processed in the gene bank to identify the presence 
of mutations in the ropB gene.
RESULTS 
A microscopic examination was performed to 
observe at M. leprae bacilli in samples obtained 
from ear incision of leprosy patients. BTA staining 
was performed using the Ziehl-Neelsen method. 
Total numbers of samples examined were 34, and 9 
of which were positive for Ziehl-Neelsen while the 
other twenty (25) were negative (Table 3). In staining 
Ziehl-Neelsen M. leprae gave red colour and looked 
straight or slightly bent (Figure 1).
Figure 1. Microscopic examination results at 100x 
magnification
There were three characteristics of patients in this 
study; the default, less sensitive to treatment and 
relapse. A default is a condition in which a PB patient 
does not take / take medication for more than 3 months 
and patients with MB over 6 months are cumulative. 
(4) Less sensitive patients were the administered 
patients with MDT but keep producing new lesion.
According to WHO, relapse patients were patient 
who successfully completes an adequate course of 
MDT, but who subsequently develops new signs and 
symptoms of the disease either during the surveillance 
period (2 years for PB and 5 years for MB leprosy) or 
thereafter.18 Based on the data obtained, most of the 
relapsed patients were as much as 59%, then default 
32% and less sensitive to treatment 9% (Figure 2).
Figure 2. Patient characteristics
Results of rpoB Mycobacterium leprae gene 
amplification derived from a clinical sample of leprosy 
patients using the Polymerase Chain Reaction (PCR) 
method. PCR product had of approximately 300 bp 
(Figure 3).  31 samples were amplified, and three 
samples were not amplified (Tabel 1). Inadequate 
cell of M. leprae within the sample perhaps was the 
main issue why the PCR amplification led to failure, 
compared to the sample which examined with 
microscopic observation method.  
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Figure 3. Visualization of PCR rpoB gene results
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300bp
The alignment of M. leprae sequencing obtained 
from leprosy patients in Jayapura showed that all was 
100% homology after performing BLAST process in 
the gene bank (Table 1). The reference strain used 
as a comparison was M. leprae TN strain (accession 
number NC_002677.1). These results indicated no 
mutations detected in our observed the M. leprae 
rpoB gene. In another study, several mutations were 
successfully detected in the rpoB M. leprae gene that 
triggered resistance to rifampicin.16,19 resistance to 
first­line (dapsone, rifampin
Table 1. Comparison between patient status, PCR result and 




Default 4/11 11/11 100% M. leprae
Relapse 4/20 18/20 100% M. leprae
Less 
sensitive
1/3 2/3 100% M. leprae
Total 9/34 31/34
DISCUSSIONS 
Detection of mutations in the rpoB M. leprae gene 
associated with rifampicin resistance is crucial. 
It is useful to comprehend the effectiveness of 
rifampicin as one of the components of MDT in the 
fight against leprosy. Papua is one of the provinces 
with high leprosy burden so that information about 
mutations, especially ropB gene that can be used to 
accelerate leprosy elimination in the Papua Province. 
Microscopic examination results showed there were 
9 positive samples containing leprosy bacilli. In 
most samples did not show the presence of M. leprae 
bacilli; however these results remained requiring 
further confirmation by molecular examination.
In the three criteria of the patients used in this study 
were defaults, and relapsed did not show significant 
improvement after having treatment with rifampicin. 
This rose concern since suspects for mutations in 
M. leprae that infected these patients. Most of the 
patients obtained in this study were relapse patients, 
and around 59% from total. Patients revealed being 
relapsed as if after RFT there found new lesions on 
the skin. Determination of patient relapse done by 
Kusta Wasor at Public Health Centre where patient 
got treatment. In addition to relapse patients, also 
found 32% of patients who had default. In this 
study also found patients who were less sensitive 
to MDT treatment by 9% which was marked by 
the emergence of new lesions during the treatment 
period. Detection of mutations in the rpoB M. leprae 
gene of the patient is essential to see the presence of 
mutations that can cause resistance. There are two 
possible patients who had been expressed RFT with 
negative skin smear returning symptom that was the 
possibility of relapse or re-infection.20
Leprosy treatment in Indonesia follows is in accordance 
with the treatment program by WHO, actually with 
Multi Drug Therapy (MDT). MDT consists of 
rifampicin, dapsone and clofazimine (lamprene).4 
Resistance to anti-leprosy drugs, such as dapsone, 
rifampicin and fluoroquinolones, has been described 
since 1967 using in vivo models.21 Molecular testing 
for leprosy drug resistance facilitates susceptibility 
testing and provides means for monitoring resistance 
globally.22 Simple PCR-based approach to rapid 
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screening of strains that have resistant alleles can 
be performed since the areas involved in rifampicin 
resistance are very limited.8 The alignment of M. leprae 
sequencing obtained from leprosy patients in 
Jayapura showed that all showed 100% homology 
after performing BLAST process in the gene bank 
(Table 1). The reference strain used as a comparison 
was M. leprae TN strain (Figure 4).
Rifampicin normally binds to RNA polymerase, 
which inhibits the transcription process in bacteria. 
A change in the order of nucleotides (mutations) 
in the gene causes rifampicin not to bind to RNA 
polymerase so that the transcription process in 
bacteria persists leaves the effects of rifampicin in 
leprosy patients to be ineffective.8,23 According to 
alignment results, M. leprae from Jayapura remained 
sensitive to rifampicin. This can be oberved in the 
results of rpoB gene sequencing that did not contain 
mutations that might trigger resistance to rifampicin. 
In such study conducted by Maladan, 2017, there 
was found a mutation at codon 477 ACT→ACC 
on M. leprae from Jayapura.24 Such mutations have 
not been reported in comparison with the existing 
publications. These mutations occur within the drug 
resistance determining region (DRDR) region.24 This 
region is an area that encodes rifampicin resistance in 
the event of mutations in it.16 Rifampicin resistance 
case reports have been widely reported that are 
associated with mutations at a particular point in the 
DRDR M. leprae region. However, the case reports 
of rifampicin resistance in Indonesia are very limited. 
Mutations reported previously were mutations at 
codon 410.25 Meanwhile, reports of cases of resistance 
from Papua have not been reported.
Case reports from several countries have also been 
reported. Some of these are mutations in H420 and 
S425.16 In addition, reports of cases of rifampicin 
resistance in leprosy patients in China have been 
reported. The resistant M. leprae strain of the patient 
contains 441 codon mutations in the rpoB gene. The 
report is the fourth mutation in China after codon 456, 
451, 481.26 Based on the results of this study it was 
known that M. leprae obtained from leprosy patients 
with a history of defaults remained susceptible 
to rifampicin. Similarly, M. leprae obtained from 
patients who showed no improvement after treatment 
was still susceptible to rifampicin. The possible 
cause of this lack of progress is due to a default. 
The existence of defaults indicates non-compliance 
with leprosy treatment. In M. leprae obtained from 
relapsed patients there was also no mutation in the 
rpoB gene. Relapse in leprosy patients other than 
due to drug resistance, can be caused by several such 
bacterial persistence, immunosuppression of the 
host,  pregnancy, the presence of advanced leprosy, 
reinfection, and factors associated with failures 
in operational health care, such as late diagnosis, 
inadequate or irregular treatment of the disease, and 
misclassification of earlier disease.27,28 In accordance 
to this study, it seemed that patients presumed to be 
relapsed due to these factors.
In conclusion, there was no mutation found in rpoB 
gene of M. leprae from Jayapura that might trigger 
resistance to rifampicin. According to the research 
findings, rifampacin remained sensetive for leprosy 
in Jayapura. Thus the relapse and default patients 
used as the subject in research were not associated 
with rifampicin resistance. It is necessary to detect 
mutations in other genes that can lead to resistance 
towards dapsone and clofazimine (lamprene) drugs, 
which are the rifampicin component of the MDT 
component in leprosy treatment. In addition, to 
support the success of treatment it definitely is 
expected leprosy patients should take medication 
regularly and intensive assistance from health 
workers and family. 
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